Patents by Inventor Poulikos Poulikakos

Poulikos Poulikakos has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and methods for treating CDK4/6-mediated cancer
    Patent number: 11541051
    Abstract: Methods for designing heterobifunctional small molecules which selectively degrade/disrupt CDK4/6 and compositions and methods of using such degraders/disruptors to treat CDK4/6-mediated cancer are provided.
    Type: Grant
    Filed: December 7, 2017
    Date of Patent: January 3, 2023
    Assignee: Icahn School of Medicine at Mount Sinai
    Inventors: Jian Jin, Xiaobao Yang, Jing Liu, Yan Xiong, Poulikos Poulikakos, Zoi Karoulia, Xuewei Wu, Tamer Ahmed
  • Compositions and methods for treating CDK4/6-mediated cancer
    Patent number: 11285150
    Abstract: Methods for designing heterobifunctional small molecules which selectively degrade/disrupt CDK4/6 and compositions and methods of using such degraders/disruptors to treat CDK4/6-mediated cancer are provided.
    Type: Grant
    Filed: December 7, 2017
    Date of Patent: March 29, 2022
    Assignee: Icahn School of Medicine at Mount Sinai
    Inventors: Jian Jin, Xiaobao Yang, Jing Liu, Yan Xiong, Poulikos Poulikakos, Zoi Karoulia, Xuewei Wu, Tamer Ahmed
  • COMPOSITIONS AND METHODS FOR TREATING CDK4/6-MEDIATED CANCER
    Publication number: 20220054488
    Abstract: Methods for designing heterobifunctional small molecules which selectively degrade/disrupt CDK4/6 and compositions and methods of using such degraders/disruptors to treat CDK4/6-mediated cancer are provided.
    Type: Application
    Filed: November 4, 2021
    Publication date: February 24, 2022
    Inventors: Jian Jin, Xiaobao Yang, Jing Liu, Yan Xiong, Poulikos Poulikakos, Zoi Karoulia, Xuewei Wu, Tamer Ahmed
  • COMPOSITIONS AND METHODS FOR TREATING CDK4/6-MEDIATED CANCER
    Publication number: 20190336503
    Abstract: Methods for designing heterobifunctional small molecules which selectively degrade/disrupt CDK4/6 and compositions and methods of using such degraders/disruptors to treat CDK4/6-mediated cancer are provided.
    Type: Application
    Filed: December 7, 2017
    Publication date: November 7, 2019
    Inventors: Jian Jin, Xiaobao Yang, Jing Liu, Yan Xiong, Poulikos Poulikakos, Zoi Karoulia, Xuewei Wu, Tamer Ahmed
  • Methods and compositions for the detection of drug resistant BRAF isoforms
    Patent number: 9481910
    Abstract: The present invention provides methods and compositions for the detection of novel BRAF splice variants that mediate resistance to BRAF and/or pan-RAF inhibitors. In particular, the invention provides PCR primer(s) to be used in the disclosed methods of detection. In some embodiments, the compositions and methods of the present invention are used to predict resistance to BRAF and/or pan-RAF inhibitors in a subject suffering from or suspected of having cancer and further provides alternative treatment strategy(ies) for a subject predicted to be resistant to BRAF and/or pan-RAF inhibitors. In a further embodiment, methods and composition for the identification of novel agents useful to overcome resistance to BRAF and/or pan-RAF inhibitors are disclosed. The present invention also provides isolated polynucleotide sequences of novel 5? BRAF splice variant(s) and proteins produced from such polynucleotide sequences as well as cell line(s) that endogenously or exogenously express the splice variant(s).
    Type: Grant
    Filed: May 24, 2012
    Date of Patent: November 1, 2016
    Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Neal Rosen, Poulikos Poulikakos, David Solit
  • METHODS AND COMPOSITIONS FOR THE DETECTION OF DRUG RESISTANT BRAF ISOFORMS
    Publication number: 20120301878
    Abstract: The present invention provides methods and compositions for the detection of novel BRAF splice variants that mediate resistance to BRAF and/or pan-RAF inhibitors. In particular, the invention provides PCR primer(s) to be used in the disclosed methods of detection. In some embodiments, the compositions and methods of the present invention are used to predict resistance to BRAF and/or pan-RAF inhibitors in a subject suffering from or suspected of having cancer and further provides alternative treatment strategy(ies) for a subject, predicted to be resistant to BRAF and/or pan-RAF inhibitors. In a further embodiment, methods and composition for the identification of novel agents useful to overcome resistance to BRAF and/or pan-RAF inhibitors are disclosed. The present invention also provides isolated polynucleotide sequences of novel 5? BRAF splice variant(s) and proteins produced from such polynucleotide sequences as well as cell line(s) that endogenously or exogenously express the splice variant(s).
    Type: Application
    Filed: May 24, 2012
    Publication date: November 29, 2012
    Inventors: Neal ROSEN, Poulikos Poulikakos, David Solit
  • Modulation of APPL expression
    Publication number: 20050065105
    Abstract: Compositions and methods are provided for modulating the expression of APPL.
    Type: Application
    Filed: February 23, 2004
    Publication date: March 24, 2005
    Inventors: Joseph Testa, Yasuhiro Mitsuuchi, Poulikos Poulikakos